Your browser doesn't support javascript.
loading
Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A; al'Absi, Mustafa; Allen, Sharon S; Carmella, Steven G; Chen, Menglan; Cinciripini, Paul M; Denlinger-Apte, Rachel; Drobes, David J; Koopmeiners, Joseph S; Lane, Tonya; Le, Chap T; Leischow, Scott; Luo, Kai; McClernon, F Joseph; Murphy, Sharon E; Paiano, Viviana; Robinson, Jason D; Severson, Herbert; Sipe, Christopher; Strasser, Andrew A; Strayer, Lori G; Tang, Mei Kuen; Vandrey, Ryan; Hecht, Stephen S; Benowitz, Neal L; Donny, Eric C.
Afiliação
  • Hatsukami DK; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Luo X; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Jensen JA; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • al'Absi M; Behavioral Medicine Laboratories, University of Minnesota Medical School, Duluth.
  • Allen SS; Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis.
  • Carmella SG; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Chen M; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Cinciripini PM; Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston.
  • Denlinger-Apte R; Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island.
  • Drobes DJ; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • Koopmeiners JS; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Lane T; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Le CT; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Leischow S; Health Sciences Research, Mayo Clinic, Scottsdale, Arizona.
  • Luo K; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • McClernon FJ; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina.
  • Murphy SE; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Paiano V; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Robinson JD; Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston.
  • Severson H; Oregon Research Institute, Eugene.
  • Sipe C; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Strasser AA; Department of Psychiatry, University of Pennsylvania, Philadelphia.
  • Strayer LG; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Tang MK; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Vandrey R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.
  • Hecht SS; Masonic Cancer Center, University of Minnesota, Minneapolis.
  • Benowitz NL; Department of Medicine, University of California, San Francisco.
  • Donny EC; Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
JAMA ; 320(9): 880-891, 2018 09 04.
Article em En | MEDLINE | ID: mdl-30193275
ABSTRACT
Importance The optimal temporal approach for reducing nicotine to minimally or nonaddictive levels in all cigarettes sold in the United States has not been determined.

Objectives:

To determine the effects of immediate vs gradual reduction in nicotine content to very low levels and as compared with usual nicotine level cigarettes on biomarkers of toxicant exposure. Design, Setting, and

Participants:

A double-blind, randomized, parallel-design study with 2 weeks of baseline smoking and 20 weeks of intervention was conducted at 10 US sites. A volunteer sample of daily smokers with no intention to quit within 30 days was recruited between July 2014 and September 2016, with the last follow-up completed in March 2017.

Interventions:

(1) Immediate reduction to 0.4 mg of nicotine per gram of tobacco cigarettes; (2) gradual reduction from 15.5 mg to 0.4 mg of nicotine per gram of tobacco cigarettes with 5 monthly dose changes; or (3) maintenance on 15.5 mg of nicotine per gram of tobacco cigarettes. Main Outcomes and

Measures:

Between-group differences in 3 co-primary biomarkers of smoke toxicant exposure breath carbon monoxide (CO), urine 3-hydroxypropylmercapturic acid (3-HPMA, metabolite of acrolein), and urine phenanthrene tetraol (PheT, indicator of polycyclic aromatic hydrocarbons) calculated as area under the concentration-time curve over the 20 weeks of intervention.

Results:

Among 1250 randomized participants (mean age, 45 years; 549 women [44%]; 958 [77%] completed the trial), significantly lower levels of exposure were observed in the immediate vs gradual reduction group for CO (mean difference, -4.06 parts per million [ppm] [95% CI, -4.89 to -3.23]; P < .0055), 3-HPMA (ratio of geometric means, 0.83 [95% CI, 0.77 to 0.88]; P < .0055), and PheT (ratio of geometric means, 0.88 [95% CI, 0.83 to 0.93]; P < .0055). Significantly lower levels of exposure were observed in the immediate reduction vs control group for CO (mean difference, -3.38 [95% CI, -4.40 to -2.36]; P < .0055), 3-HPMA (ratio of geometric means, 0.81 [95% CI, 0.75 to 0.88]; P < .0055), and PheT (ratio of geometric means, 0.86 [95% CI, 0.81 to 0.92]; P < .0055). No significant differences were observed between the gradual reduction vs control groups for CO (mean difference, 0.68 [95% CI, -0.31 to 1.67]; P = .18), 3-HPMA (ratio of geometric means, 0.98 [95% CI, 0.91 to 1.06]; P = .64), and PheT (ratio of geometric means, 0.98 [95% CI, 0.92 to 1.04]; P = .52). Conclusions and Relevance Among smokers, immediate reduction of nicotine in cigarettes led to significantly greater decreases in biomarkers of smoke exposure across time compared with gradual reduction or a control group, with no significant differences between gradual reduction and control. Trial Registration clinicaltrials.gov Identifier NCT02139930.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Produtos do Tabaco / Nicotina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Produtos do Tabaco / Nicotina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2018 Tipo de documento: Article